Cevimeline is a muscarinic agonist with parasympathomimetic activities that is used for the symptomatic treatment of dry mouth in patients with Sjögren's Syndrome. A medication used to treat dry mouth caused by a type of immune disorder.
- Mechanism
- Curator reviewed
Muscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which help to stimulate secretion in salivary glands, and their activation generally results in smooth muscle contraction and increased glandular secretions. Therefore, as saliva excretion is increased, the symptoms of dry mouth are relieved.
- Primary indication
- For the treatment of symptoms of dry mouth in patients with Sjögren's syndrome.Curator reviewed · 1 structured indication
- Formula / weight
- C10H17NOS · 199.313 g/mol (avg)
- First approval
- United States, 2000
- Code names
- Sni 2011
- Brand names
Resolves to
WUTYZMFRCNBCHQ-LHIURRSHSA-NSMILESCC1O[C@@]2(CS1)CN1CCC2CC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Cevimeline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account